Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial
Background Cholesterol reduction with proprotein convertase subtilisin-kexin type 9
inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients …
inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients …
Effects of alirocumab on cardiovascular events after coronary bypass surgery
SG Goodman, PE Aylward, M Szarek… - Journal of the American …, 2019 - jacc.org
Background: Patients with acute coronary syndrome (ACS) and history of coronary artery
bypass grafting (CABG) are at high risk for recurrent cardiovascular events and death …
bypass grafting (CABG) are at high risk for recurrent cardiovascular events and death …
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Abstract Aims The third Universal Definition of Myocardial Infarction (MI) Task Force
classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand …
classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand …
Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function
J Schremmer, L Busch, S Baasen, Y Heinen… - Microvascular …, 2023 - Elsevier
Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively
decrease low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events in …
decrease low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events in …
Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
Objective: We aimed to evaluate alirocumab-and evolocumab-related adverse events (AEs)
in real-world compared with all other drugs, overall and by gender and age subgroups; we …
in real-world compared with all other drugs, overall and by gender and age subgroups; we …
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy …
Benefits and safety on statins have been well-established over 20 years of research. Despite
this, the vast majority of patients are not adequately treated and do not achieve the low …
this, the vast majority of patients are not adequately treated and do not achieve the low …
New targets in atherosclerosis: vascular smooth muscle cell plasticity and macrophage polarity
Purpose Despite an increase in treatment options, and substantial reductions in
cardiovascular mortality over the past half-century, atherosclerosis remains the most …
cardiovascular mortality over the past half-century, atherosclerosis remains the most …
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without …
J Peng, MM Liu, JL Jin, YX Cao, YL Guo… - Cardiovascular …, 2020 - Springer
Background Whether plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels is
a predictor for cardiovascular outcomes has currently been controversial. No data is …
a predictor for cardiovascular outcomes has currently been controversial. No data is …
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy
TA Jacobson, MK Cheeley, PH Jones… - Journal of clinical …, 2019 - Elsevier
Background It is important to understand patients' experiences of statin-associated adverse
effects to potentially identify those at risk for stopping treatment. Objective The goal of the …
effects to potentially identify those at risk for stopping treatment. Objective The goal of the …
[PDF][PDF] Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction …
GG Schwartz, M Szarek, DL Bhatt, VA Bittner… - Eur Heart …, 2023 - scholar.archive.org
Abstract 1 Aims Long-term, placebo-controlled cholesterol-lowering trials have
demonstrated legacy 2 effects (clinical benefits that persist or emerge after trial end). It is …
demonstrated legacy 2 effects (clinical benefits that persist or emerge after trial end). It is …